Seaport Therapeutics CEO Daphne Zohar (L) and chairman Steve Paul

Up­dat­ed: Steve Paul, Daphne Zo­har re­unite for an­oth­er neu­ro start­up af­ter Karuna suc­cess

That was quick.

One month af­ter Bris­tol My­ers Squibb com­plet­ed its $14 bil­lion ac­qui­si­tion of Karuna Ther­a­peu­tics, the CNS biotech’s ex­ec­u­tive and found­ing team are back with an­oth­er neu­ropsy­chi­atric start­up al­ready in the clin­ic to make bet­ter ver­sions of ac­tive drugs.

PureTech Health, the biotech that formed Karuna and re­ceived about a 59x re­turn on its ini­tial in­vest­ment, has launched Sea­port Ther­a­peu­tics and reeled in $100 mil­lion from fa­mil­iar in­vestors ARCH Ven­ture Part­ners, Sofinno­va In­vest­ments and Third Rock Ven­tures. Post-Se­ries A, PureTech will hold about 61.5% eq­ui­ty own­er­ship, the com­pa­ny said Tues­day morn­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.